Fosun Pharma returns funds used for working capital

Shanghai Fosun Pharmaceutical Group (the "Company") announced that its project implementation entities have fully returned the funds temporarily used to supplement working capital. This action was approved at the ninth session of the 54th meeting of the board and the sixth meeting of the supervisory board in July 2024. The funds, not exceeding CNY 41,000,000, were drawn from proceeds of the Company’s 2022 non-public A-share offering, and were designated for temporary working capital supplementation. As of July 7, 2025, all funds have been returned to the dedicated fund accounts. The Company has notified China International Capital Corporation Limited, the recommending institution for the offering, of the completion of the return.